… Lacidipine was first developed in 1984, with the aim of … to review the clinical safety
profile of lacidipine with the help of … the outcome of calcium antagonist treatment in prospective, …

… Summary: The clinical safety of the new dihydropyridine calcium antagonist lacidipine was
assessed in 14 clinical trials, including 1,372 patients treated with lacidipine and 687 treated …

… blood pressure monitoring, lacidipine 2 to 8mg administered … treatment with lacidipine 2 to
8 mg/dayfor 1 to 4 months in dose-finding studies. When administered once daily, lacidipine 4 …

… In the present analysis, we took lacidipine, a slowonset, long-… we reviewed the clinical safety
profile of lacidipine with the help … data from 16 590 patients treated with lacidipine (Table 1), …

… The aim of this study was to assess the effectiveness of lacidipine, a calcium channel blocker
with a better tolerability in comparison to nifedipine and other calcium antagonists [16, 17], …

… The human pharmacokinetics of lacidipine were not well characterised using the … on
lacidipine has been published and reports the main characteristics of the compound.[11] Lacidipine …

… Calcium antagonists are effective and safe agents for the treatment of essential hypertension.
They lower elevated blood pressure by reducing the increase in total peripheral resistance…

… 3 Heart rate on treatment with lacidipine alone was significantly … heart disease until shown
to be safe. Finally, with regard to both … These aspects werenot formally examinedin this study, …

… The safety profile of the dihydropyridine CCB is generally … lacidipine (4%) than with other
CCB (14%) (3) . In a direct comparison, edema was observed in 10% of patients on lacidipine …

… whether antihypertensive treatment with the calcium antagonist lacidipine can … treatment
at 6 mg/d) lacidipine administration and 2 weeks after withdrawal of chronic (32-week) treatment…